
Dublin /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/hcv3cc/global) has announced the addition of the “Global Biosimilars Market, 2015 - 2025” report to their offering.

Characterised by increased utility in chronic diseases and capital intensive manufacturing, the global biopharmaceutical market is expanding robustly. As the demand for biologics is increasing continuously, manufacturers are on the lookout for novel strategies that will help them attain maximum returns on investment. Derived from biological elements, biologic medications have transformed the treatment paradigm of life threatening, debilitating diseases. However, such drugs come at staggering prices in the market. Hence, cheaper biological products have become an economic and healthcare requisite.

The Global Biosimilars Market, 2015 - 2025 report provides an extensive study of the rapidly growing biosimilars market. With the blockbuster biologics losing patent protection and biotechnology industry striving to minimize costs, biosimilars are being viewed as viable substitutes to the highly expensive biological medications. The study presents an in-depth review of the developments in established markets and emerging regions, with respect to the market landscape, global and local players, regulatory scenario and emerging opportunities. It provides a detailed analysis of the worldwide pipeline of biosimilars on key parameters such as product categories, indications, biosimilar targets and status of development.

The study presents a comprehensive view of key product classes into which biosimilars can be categorized; these include monoclonal antibodies (mAbs), insulin, interferons, G-CSF/ GM-CSF, erythropoietins and others. We have highlighted some of the important aspects specific to these product categories including regulatory guidelines, development challenges, marketed / pipeline biosimilars, sales data (where available) and information on patent expiry of the reference products.

The report assesses some of the key drivers that have governed the evolution of biosimilars market over the past several years along with an elaborate discussion on the future trends that will shape the market in the coming years. One of the focus areas of this study is to estimate size of the future opportunity in the biosimilars market over the next decade, segmented on the basis of geographical clusters and product categories.

The study also provides information on some of the most recent activities in this market; amongst others, these include growing collaborations, investment activity and technological advancements. In addition to some of the well-known benefits and a promising outlook, the study also highlights considerable challenges currently prevalent in the market. Examples of such challenges include manufacturing complexities, heterogeneous regulatory framework, and associated safety and efficacy issues. Nevertheless, these challenges are paving the way for new strategies and technological improvements, which will indeed be advantageous in the long run.

The report provides market forecasts for the time period 2020 and 2025. The research, analysis and insights presented in this report is backed by a deep understanding of key insights gathered both from secondary and primary research.

Example Highlights:
- The market is driven by the presence of a growing pipeline; during our research, we identified over 600 biosimilar products across various product categories covering mAbs, insulin, interferons amongst others.
- Specifically, mAb biosimilars being developed for multiple diseases form a sizeable proportion of the preclinical/clinical development pipeline. In our pipeline, we reviewed around 200 mAb biosimilars. Neupogen, Enbrel and Humira, owing to their...
staggering revenues, are examples of some of the most popular target reference products.

- The emerging pharmaceutical markets of Asia, Latin America and Eastern Europe, with benefits such as lower labour costs, access to regional / domestic markets and, most importantly, relaxed regulatory requirements serve as attractive destinations for biosimilars research and commercialisation. This geographical cluster currently dominates the market with respect to the number of approved products.

- In order to exploit the advantages of combined resources and use licensed assets, stakeholders have announced numerous collaborations in the recent past. During our research, we identified around 70 partnerships which have taken place in the biosimilar market over the last few years.

- Looking at the ongoing focus, the market is well positioned to achieve a robust growth in the coming decade as the number of patent expiries grows and the legal and regulatory squabbles are sorted out; based on a very comprehensive analysis, we have projected the market to be worth USD 32 billion worldwide by 2025.

- Although emerging markets have been on a fast track in the recent past, the desired market uptake in the US and Europe will drive the market to attain its peak potential.

**Key Topics Covered:**

1. Preface
2. Executive Summary
3. Introduction
4. Biosimilars: Developed Markets
5. Biosimilars: Emerging Markets
6. Global Market Overview
7. Market Dynamics
8. Monoclonal Antibody Biosimilars
9. Insulin Biosimilars
10. Biosimilar Interferons
11. Other Leading Biosimilar Markets
12. Recent Developments
13. Outsourcing of Biosimilars
14. Market Forecast
15. Conclusion
16. Interview Transcripts
17. Appendix 1: Tabulated Data
18. Appendix 2: List of Companies and Organisations

- 3S Bio Inc.
- Abbott
- AbZ Pharma
- Accord Healthcare Ltd.
- Actavis
- Aequus BioPharma
- AET Biotech
- Agila Biotech
- Alvartis Pharma
- Alvogen
- Amega Biotech
- Amgen
- Anhui Anke Biotechnology (Group) Co., Ltd
- Anika Therapeutics
- ANMAT (Argentina)
- Apotex
- Aprogen Inc.
- AryoGen
- ASKA Pharmaceutical Co. Ltd.
- Aspen Pharmacare Australia
- Avesthagen
- Axicorp GmbH
- AXXO GmbH
- HygeneBiopharm Co. Ltd.
- iBio Inc.
- IDDI
- IDEC Pharmaceuticals
- Inbiopro
- INC Research, LLC
- Incepta Pharmaceuticals Ltd.
- Inno Bio Ventures Sdn Bhd.
- Innogene
- Innoven Biologics
- Insmed
- Instituto Vital Brazil
- Intas Pharmaceuticals
- Intertek
- InVentiv Health
- Ipca Laboratories
- IsuAbxis
- Itochu Chemical Frontier Corporation
- Janssen Biotech
- JCR Pharmaceuticals
- Johnson & Johnson
- Julphar
- Kawsar Biotech Company
- Kee Pharma
- Kemwell Biopharma
- Kern Pharma
- Kissei Pharmaceuticals
- KlarvoyantBiogenics
- Kocak Pharma
- Kun Wha Pharmaceutical Company
- La Renon
- LaboratoriosVarifarma
- Landsteiner Laboratories
- LG Lifesciences
- Liomont
- LivzonMabpharm
- Lonza
- Lupin
- Mabion
- mAbxience S.A
- MannKind Corp
- Marvel Life Sciences
- Medicago
- MEDICE Arzneimittel Putter
- Meiji Seika Pharma Co., Ltd.
- Merck & Co
- Merck KGaA
- Merieux Alliance
- MGC Pharma
- Micro Labs
- Minapharm Pharmaceuticals
- Ministry for Health Labour and Welfare (MHLW), Japan
- Ministry of Food and Drug Safety (MFDS), Korea
- Mitsubishi Tanabe Pharma
- MJ Biopharm Pvt. Ltd.
- Mochida Pharmaceutical
- Momenta Pharma
- MPI Research
- Mundipharma International Corporation
- Mylan
- Nanogen Biopharmaceuticals
- Napp Pharmaceuticals
- Natco Pharma
- National Health Surveillance Agency (ANVISA)
- National Institute for Health and Clinical Excellence
- NCPC Genentech Biotechnology Co. Ltd.
- Neiss Labs Pvt. Ltd.
- Neogenica Bioscience Ltd
- Neudone
- Nichi-Iko Pharmaceuticals
- Nippon Kayaku
- Novartis
- Novo Nordisk
- NPS Pharmaceuticals
- Oncobiologies
- OrygenBiotecnologia
- Panacea Biotec
- PanGen Biotech
- Paras Biopharmaceuticals
- Parexel
- Patheon
- Pfenex
- Pfizer
- Pharmaceutical Product Development Inc.
- Pharmacia
- PharmaPraxis
- PlantForm Corporation
- Pliva
- PLIVA
- Probiomed
- ProFibrix BV
- Prolong Pharmaceuticals
- Protalix Biotherapeutics
- Qilu Pharmaceutical Co., Ltd.
- Quintiles
- Raichem Lifesciences
- Ranbaxy
- Ratiopharm
- Reliance GeneMedix Plc
- Reliance Life Sciences
- RentschlerBiotechnologie GmbH
- RG Pharmaceutica
- RheinMinapharm
- Richter-Helm BioTec GmbH
- Roche
- RPG Life Sciences
- Salix Pharmaceuticals, Ltd.
- Samarth Life Sciences
- Samsung Bioepis
- Sandoz
- Sanofi Aventis
- Sanwa Kagaku Kenkyusho Co., Ltd.
- Schering-Plough
- Sci Gen Australia
- Sedico
- Serum Institute of India
- SGS Life Science Services
- Shandong KexingBioproducts Co., Ltd
- Shanghai Biomabs Pharmaceuticals Co Ltd
- Shanghai Celgen Bio-Pharmaceutical
- Shanghai CP Guojian Pharmaceutical
- Shanghai Fosun Pharmaceutical
- Shanghai Zhangjiang Biotechnology Limited Company
- Shantha Biotech
- Shreya Life Sciences
- Sicor Biotech
- Simcere Pharmaceutical Group
- South Korea's Ministry of Food and Drug Safety
- Spectrum Pharmaceuticals
- StadaArneimittel AG
- STC Biologies
- Stelis Biopharma
- Strides Arcolab Limited
- Symbiosis
- Synthon Pharmaceuticals
- Taj Pharmaceuticals
- Takeda Pharmaceuticals
- TCI Generics
- Tecpar
- Teva
- The Medicines Company
- Torrent Pharmaceuticals
- Toyota Tshuho Corp.
- TTK Healthcare
- UMN Pharma
- United Biotech
- United Therapeutics Corp
- USFDA
- USV Limited
- VHB Life Sciences Ltd.
- Virchow Biotech
- Viapro
- Warner-Lambert
- Watson Pharmaceuticals
- WHO
- WIL Research
- Wockhardt
- Wyeth
- Xiamen Amyotop Biotech
- Xian Janssen
- Yoshindo
- Zenyaku Kogyo
- Zhejiang Hisun Pharma
- Zhejiang Huahai Pharmaceutical Co. Ltd.
- ZhongshanHygeneBiopharm
- Zuventus Healthcare Ltd.
- ZydusCadila
- Zyphars Pharmaceuticals

For more information visit http://www.researchandmarkets.com/research/hcv3cc/global.
YOU MAY ALSO LIKE...

U.S. Biosimilars Market Worth $11B By 2020 - 22% CAGR Forecast For Global Biosimilar Industry In New Research Reports
The Global & USA Biosimilar Market Analysis to 2021 research report indicates a high market potential for biosimilars by 2019 when 50% of the biologics market is forecast to belong to off-patent drugs as there is tremendous interest by big pharma and generics companies in biosimilars industry.

Pharma Leader Series: 25 Top Biosimilar Drug Manufacturers 2016-2026
Who are the most important and promising biosimilar drug companies? And what are their sales potentials? Discover, in our updated survey, organisations’ outlooks from 2016. There you see results, trends, opportunities and revenue forecasting.

Global Humira (Adalimumab) Biosimilars Clinical Trial Insight Report 2016 - Humira Had Topped US$ 14B Of Sales Globally - Research And...
Markets
Research and Marketshas announced the addition of the "Humira Biosimilars Clinical Trial Insight" clinical trials to their offering.

Herceptin (Trastuzumab) Biosimilar Clinical Trial Insight - Research And Markets
Research and Marketshas announced the addition of the "Herceptin (Trastuzumab) Biosimilar Clinical Trial Insight" clinical trials to their offering.

Global Clinical Insight On 17 Biosimilar Versions Of Remicade (Infliximab) Drug In Clinical Pipeline 2016 - Research And Markets
Research and Marketshas announced the addition of the "Remicade (Infliximab) Biosimilar Clinical Trial Insight" clinical trials to their offering.

Increasing Need For Cost-Effective Treatment Drives Global Biosimilars Market To Grow At A CAGR Of 55.52% During 2016-2020: MarketResearchReports.biz

Global Biosimilars Market Is Expected To Reach $35B By 2020, Finds New Report

European Biosimilars Market Opportunity Outlook Report 2015-2020

Biosimilars In Emerging Economies - Advanced Recombinant Technology Platforms And Low Cost Manufacturing Put India And China At A Strategic Advantage In Biosimilar Production

Celltrion And Medidata Team Up To Transform Global Clinical Trials For Biosimilars

Global Biosimilar Market Outlook 2022 - Entry Of Biosimilars In The US Market & Rising Incidences Of Chronic Diseases - Research And Markets